NurExone Biologic Secures C$1.2M Funding and Appoints FDA-Experienced R&D Director
Summary
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D DirectorTORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (NurExone or the Company), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that, subject to TSX Venture Exchange (TSXV) approval, it has closed a non-brokered private placement of 856,996 units (Units) at a price of C per Unit for aggregate gross proceeds of C (the Offering). With over 15 years of R&D and chemistry, manufacturing and controls expertise, Dr. Kizhner has led groundbreaking initiatives in therapeutic protein development and dietary supplements. At Protalix Biotherapeutics, she played a pivotal role in developing biologics, including FDA- and EMEA-approved treatments for Fabry disease. Dr. Kizhner, who holds a Ph.D. in Biotechnology and Food Engineering from the Technion Israel Institute of Technology, brings expertise and leadership to guide NurExones promising therapies through the upcoming stages of development and approvals.NurExone Biologic Inc. is a TSXV and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered Central Nervous System injuries. The Companys first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in of laboratory rats when administered intranasally.